New 'chemical probes' to examine the role of the hFPRL1 (or ALXR) receptor in inflammation

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 23, 2007, Pages 6633-6637

  Frohn, Mike ^a   Xu, Han ^a   Zou, Xiaoming ^a   Chang, Catherine ^a   McElvaine, Michele ^a   Plant, Matthew H ^a   Wong, Min ^a   Tagari, Philip ^a   Hungate, Randall ^a   Bürli, Roland W ^a  

^a AMGEN INC   (United States)

Author keywords

Benzimidazole; GPCR; hFPRL1; IL 6; Neutrophil migration

Indexed keywords

BENZIMIDAZOLE DERIVATIVE; FORMYLPEPTIDE RECEPTOR LIKE 1; PYRAZOLONE;

ARTICLE; DOSE RESPONSE; DRUG EFFECT; DRUG IDENTIFICATION; DRUG INHIBITION; DRUG STRUCTURE; ENANTIOMER; IN VITRO STUDY; INFLAMMATION; NONHUMAN;

ANIMALS; BENZIMIDAZOLES; CELL MIGRATION INHIBITION; CHEMOTAXIS, LEUKOCYTE; CHO CELLS; CRICETINAE; CRICETULUS; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; MOLECULAR PROBES; NEUTROPHILS; RECEPTORS, FORMYL PEPTIDE; RECEPTORS, LIPOXIN;

EID: 35648947871     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.09.043     Document Type: Article

References (37)

1. For reviews, see. Migeotte I., Communi D., and Parmentier M. Cytokine Growth Factor Rev. 17 (2006) 501
2. Selvatici R., Falzarano S., Mollica A., and Spisani S. Eur. J. Pharmacol. 534 1-3 (2006) 1
3. Fu H., Karlsson J., Bylund J., Movitz C., Karlsson A., and Dahlgren C. J. Leukocyte Biol. 79 (2006) 247
4. Iribarren P., Zhou Y., Hu J., Le Y., and Wang J.M. Immunol. Res. 31 (2005) 165
5. Le Y., Zhou Y., Tao H., and Wang J.M. Clin. Exp. Allergy Rev. 4 2 suppl (2004) 155
6. Le Y., Murphy P.M., and Wang J.M. Trends Immunol. 23 (2002) 541
7. Le Y., Oppenheim J.J., and Wang J.M. Cytokine Growth Factor Rev. 12 (2001) 91
8. Ye R.D., Cavanagh S.L., Quehenberger O., Prossnitz E.R., and Cochrane C.G. Biochem. Biophys. Res. Commun. 184 (1992) 582
9. For a lead reference, see. Devchand P.R., Arita M., Hong S., Bannenberg G., Moussignac R.-L., Gronert K., and Serhan C.N. FASEB J. 17 (2003) 652
10. Le Y., Gong W., Tiffany H.L., Tumanov A., Nedospasov S., Shen W., Dunlop N.M., Gao J.-L., Murphy P.M., Oppenheim J.J., and Wang J.M. J. Neurosci. 21 RC123 (2001) 1
11. Ying G., Iribarren P., Zhou Y., Gong W., Zhang N., Yu Z.-X., Le Y., Cui Y., and Wang J.M. J. Immunol. 172 (2004) 7078
12. Su S.B., Gong W., Gao J.-L., Shen W., Murphy P.M., Oppenheim J.J., and Wang J.M. J. Exp. Med. 189 (1999) 395
13. Le Y., Yazawa H., Gong W., Yu Z., Ferrans V.J., Murphy P.M., and Wang J.M. J. Immunol. 166 (2001) 1448
14. 1g and references therein.
15. For a recent review, see. Chiang N., Serhan C.N., Dahlén S.-E., Drazen J.M., Hay D.W.P., Rovati G.E., Shimizu T., Yokomizo T., and Brink C. Pharmacol. Rev. 58 (2006) 463
16. Fiore S., Ryeom S.W., Weller P.F., and Serhan C.N. J. Biol. Chem. 267 (1992) 16168
17. Serhan C.N. Prostaglandins Other Lipid Mediat. 68-69 (2002) 433
18. Fiore S., Maddox J.F., Perez H.D., and Serhan C.N. J. Exp. Med. 180 (1994) 253
19. Takano T., Fiore S., Maddox J.F., Brady H.R., Petasis N.A., and Serhan C.N. J. Exp. Med. 185 (1997) 1693
20. Maddox J.F., Hachicha M., Takano T., Petasis N.A., Fokin V.V., and Serhan C.N. J. Biol. Chem. 272 (1997) 6972
21. Brenner P.S., and Krakauer T. Curr. Med. Chem. Anti-Inflammatory & Anti-Allergy Agents 2 (2003) 274
22. Christie P.E., Spur B.W., and Lee T.H. Am. Rev. Respir. Dis. 145 (1992) 1281
23. Fiorucci S., Wallace J.L., Mencarelli A., Distrutti E., Rizzo G., Farneti S., Morelli A., Tseng J.-L., Suramanyam B., Guilford W.J., and Parkinson J.F. Proc. Natl. Acad. Sci. 101 (2004) 15736
24. Machado F.S., Johndrow J.E., Esper L., Dias A., Bafica A., Serhan C.N., and Aliberti J. Nat. Med. 12 (2006) 330
25. Bandeira-Melo C., Bozza P.T., Diaz B.L., Cordiero R.S.B., Jose P.J., Martins M.A., and Serhan C.N. J. Immunol. 164 (2000) 2267
26. Soyombo O., Spur B.W., and Lee T.H. Allergy 49 (1994) 230
27. Lee T.H., Horton C.E., Kyan-Aung U., Haskard D., Crea A.E., and Spur B.W. Clin. Sci. 77 (1989) 195
28. Ramstedt U., Serhan C.N., Nicolaou K.C., Webber S.E., Wigzell H., and Samuelsson B. J. Immunol. 138 (1987) 266
29. Gavins F.N.E., Yona S., Kamal A.M., Flower R.J., and Perretti M. Blood 101 (2003) 4140
30. Perretti M., Chiang N., La M., Fierro I.M., Marullo S., Getting S.J., Solito E., and Serhan C.N. Nat. Med. 8 (2002) 1296
31. Bürli R.W., Xu H., Zou X., Muller K., Golden J., Frohn M., Adlam M., Plant M.H., Wong M., McElvain M., Regal K., Viswanadhan V., Tagari P., and Hungate R. Bioorg. Med. Chem. Lett. 16 (2006) 3713
32. 2+] was monitored by luminescence emitted by aequorin.
33. All indole 2-carboxylates were obtained from commercial sources. The benzimidazole 2-carboxylate was prepared from 4-methoxy-o-phenylenediamine dihydrochloride: {A figure is presented}.
34. 3.
35. α15 protein. The assay was performed as described.
36. Frevert C.W., Wong V.A., Goodman R.B., Goodwin R., and Martin T.R. J. Immunol. Methods 213 (1998) 41
37. 2 in a tissue culture incubator for 18 h. The final percent concentration whole blood was 50%. The final DMSO concentration was 0.1%. The total volume for all assays was 200 μL. After 18 h, supernatant/plasma was collected and assayed immediately or frozen at -80 °C using IL-6 detection MSD ECL based plates. Fifty microliters of supernatant was added to MSD plates and incubated for 1 h on a shaker. The plates were then washed once with 200 μL of PBS/0.1% Tween. Twenty-five microliters of detection antibody diluted in antibody diluent (1 μg/mL), and 125 μL of 2× Read Buffer P were added, and the plates were incubated for 1 h on a shaker, protected from light. ECL was measured using the SECTOR HTS Imager (MSD, Gaithersburg, MD).